Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-Year Randomised Double-Blind Placebo-Controlled International Multicentre Study

Trial Profile

Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-Year Randomised Double-Blind Placebo-Controlled International Multicentre Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Left ventricular dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms BEAUTIFUL
  • Sponsors IRIS; Servier
  • Most Recent Events

    • 28 Oct 2009 Results of new sub-analyses were presented today at the 2009 Canadian Cardiovascular Congress, according to a Montreal Heart Institute media release.
    • 31 Aug 2009 Subgroup results presented at ESC 2009, as reported in a Servier media release.
    • 31 Aug 2008 Results presented at ESC 2008 and published in the Lancet.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top